The effect of current management on morbidity and mortality in hospitalised adults with funguria

The Journal of Infection
Christine SimpsonStephen D Shafran

Abstract

To compare morbidity and mortality in inpatients with asymptomatic funguria between those treated and those observed for funguria. Retrospective analyses were performed in 149 consecutive adult tertiary care inpatients with asymptomatic funguria. The primary endpoints were death, length of hospitalisation and progression to invasive fungal infection (IFI). Of the 149 subjects, 70% were female, 55% were >65 years, recent antibiotic and urinary catheter use occurred in >70%, diabetes in 32%, recent ICU admission in 29%, and concomitant bacteriuria in 28%. Forty-seven percent did not receive active intervention. Of the remainder, 46% were managed by controlling or eliminating risk factors for funguria or progression to IFI; fluconazole or amphotericin B were used to treat the other 54%. Fourteen percent died and 2.7 % progressed to IFI, with no significant difference between the treated versus observed groups for either endpoint (p>0.2). Median length of hospitalisation was significantly greater in the treated group (p<0.01); multivariate analysis demonstrated an exclusive relationship to the greater number of risk factors present in the treated group. Asymptomatic funguric patients who were managed with risk reduction and/or anti...Continue Reading

References

Aug 1, 1992·American Journal of Infection Control·D J WeberK K Hoffmann
Dec 8, 1983·The New England Journal of Medicine·L E NicolleJ A MacDonell
May 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·H S Leu, C T Huang
Jan 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J F FisherJ D Sobel
Oct 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P Fan-HavardR H Eng
Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C A KauffmanW E Dismukes

❮ Previous
Next ❯

Citations

Sep 22, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S G RevankarJ D Sobel
Apr 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jack D SobelCheryl A Newman
Sep 9, 2005·Critical Care Medicine·Andrew F ShorrMarin H Kollef
Apr 22, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard H DrewJohn R Perfect
Feb 4, 2014·Infectious Disease Clinics of North America·Carol A Kauffman
Dec 19, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter G PappasJack D Sobel
May 24, 2006·Pediatric Clinics of North America·Steven L Chang, Linda D Shortliffe
Jan 31, 2006·Memórias do Instituto Oswaldo Cruz·Xisto Sena PassosMaria do Rosário Rodrigues Silva
Dec 25, 2007·Revista Do Instituto De Medicina Tropical De São Paulo·Elza Helena da SilvaClaudete Rodrigues Paula
Apr 4, 2007·Expert Review of Anti-infective Therapy·Anurag N Malani, Carol A Kauffman
Oct 20, 2018·Hospital Practice·Javier Pemán, Alba Ruiz-Gaitán
Mar 30, 2019·Journal of Endourology·Todd YeciesMichelle Jo Semins
Oct 28, 2019·World Journal of Urology·Zekaver Odabasi, Ali Mert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
L G JacobsN Fox
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
C A KauffmanW E Dismukes
© 2021 Meta ULC. All rights reserved